Argenica Therapeutics (AGN) investor relations material

Investment highlights

• Xaranetide (ARG-007) is a first-in-class neuroprotective drug with strong preclinical efficacy in reducing brain injury after stroke and other insults.

• Phase 2 clinical trial showed a severity-dependent treatment effect, with significant benefits in moderate to severe stroke patients.

• Statistically significant improvements in functional outcomes (mRS 0-3) were observed in patients with larger infarct cores.

• Phase 2 data supports a targeted Phase 2b trial in moderate to severe stroke patients, with a world-leading clinical advisory committee guiding trial design.

• ARG-007 has demonstrated efficacy in preclinical studies for traumatic brain injury and hypoxic ischaemic encephalopathy, expanding its potential applications.

Financial and operational metrics

• $6.4M cash at bank as of June 30, 2026, and a market cap of $20M based on July 23, 2026, closing price.

• 128.5M shares on issue, with 37% held by the top 20 shareholders.

• Positive data reported from the Phase 2 stroke trial.

Clinical trial results and drug profile

• ARG-007 significantly reduced infarct volume and improved functional outcomes in patients with severe strokes (ASPECTS ≤8).

• Patients with larger infarct cores treated with ARG-007 had better three-month functional outcomes (mRS 0-3) compared to placebo.

• The drug is stable for up to two years, easy to store, and fits seamlessly into clinical workflows, supporting rapid administration in acute care settings.